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Abstract
Introduction: Although less invasive than pulmonary artery catheters (PACs), arterial pulse pressure analysis
techniques for estimating cardiac output (CO) have not been simultaneously compared to PAC bolus
thermodilution CO (COtd) or continuous CO (CCO) devices.
Methods: We compared the accuracy, bias and trending ability of LiDCO™, PiCCO™ and FloTrac™ with PACs (COtd,
CCO) to simultaneously track CO in a prospective observational study in 17 postoperative cardiac surgery patients
for the first 4 hours following intensive care unit admission. Fifty-five paired simultaneous quadruple CO
measurements were made before and after therapeutic interventions (volume, vasopressor/dilator, and inotrope).
Results: Mean CO values for PAC, LiDCO, PiCCO and FloTrac were similar (5.6 ± 1.5, 5.4 ± 1.6, 5.4 ± 1.5 and 6.1 ±
1.9 L/min, respectively). The mean CO bias by each paired method was -0.18 (PAC-LiDCO), 0.24 (PAC-PiCCO), -0.43
(PAC-FloTrac), 0.06 (LiDCO-PiCCO), -0.63 (LiDCO-FloTrac) and -0.67 L/min (PiCCO-FloTrac), with limits of agreement
(1.96 standard deviation, 95% confidence interval) of ± 1.56, ± 2.22, ± 3.37, ± 2.03, ± 2.97 and ± 3.44 L/min,
respectively. The instantaneous directional changes between any paired CO measurements displayed 74% (PAC-
LiDCO), 72% (PAC-PiCCO), 59% (PAC-FloTrac), 70% (LiDCO-PiCCO), 71% (LiDCO-FloTrac) and 63% (PiCCO-FloTrac)
concordance, but poor correlation (r
2 = 0.36, 0.11, 0.08, 0.20, 0.23 and 0.11, respectively). For mean CO < 5 L/min
measured by each paired devices, the bias decreased slightly.
Conclusions: Although PAC (COTD/CCO), FloTrac, LiDCO and PiCCO display similar mean CO values, they often
trend differently in response to therapy and show different interdevice agreement. In the clinically relevant low CO
range (< 5 L/min), agreement improved slightly. Thus, utility and validation studies using only one CO device may
potentially not be extrapolated to equivalency of using another similar device.
Introduction
Although the pulmonary arterial catheter (PAC) mea-
sures cardiac output (CO) easily at the bedside in criti-
cally ill patients [1-3], the recent trend in intensive care
unit (ICU) monitoring is toward minimally invasive
methods [4-8]. Arterial pulse contour and pulse power
analyses have emerged as less invasive alternatives to
PAC-derived CO measures [9,10]. The accuracy of these
devices for PAC-derived CO measures has not been sys-
tematically compared in response to therapies other
than volume resuscitation [11,12]. These devices use
different calibration schema and model the transfer of
a r t e r i a lp u l s ep r e s s u r et os t r o k ev o l u m ed i f f e r e n t l y .
Thus, their cross-correlations may not be assumed to be
similar. The LiDCO Plus™ (LiDCO Ltd, London, UK)
uses a transthoracic lithium dilution estimate of CO for
calibration, whereas the PiCCO Plus™ (Pulsion Ltd,
Munich, Germany) uses a transthoracic thermodilution
approach to compensate for interindividual differences
in arterial compliance [13-15]. The FloTrac™ calculates
CO from the pulse contour using a proprietary algo-
rithm and patient-specific demographic data [16] with,
however, inconsistent reports of accuracy [17-20].
Although all devices have been compared individually
to PAC-derived estimates of CO, none have been com-
pared to each other [21]. Oxygen delivery (DO2)
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in selected patient groups [22]. Thus, knowing the
degree to which different systems co-vary is important if
one is to use these outcome studies in a general fashion
to define the utility of all minimally invasive monitoring
systems. Accordingly, in this study, we cross-compared
the CO values and their changes in a critically ill patient
cohort in whom active changes in blood volume, vaso-
motor tone and contractility were induced by specific
therapies. We compared three pulse contour devices
(LiDCO Plus, PiCCO Plus and FloTrac) (Edwards Life-
sciences, Irvine, CA, USA) and two PAC thermodilution
techniques: CO by thermodilution (COtd) and continu-
ous cardiac output (CCO) in postoperative cardiac sur-
gery patients during the first 4 postoperative ICU hours
when most of the aggressive treatments occurred. To
minimize initial CO differences, we calibrated the
PiCCO and LiDCO devices using the initial PAC CO
values, whereas the FloTrac did not allow external
calibration.
Materials and methods
The study was approved by our Institutional Review
Board, and all patients provided signed informed con-
sent. Twenty postcardiac surgery patients (age range, 54
to 82 yr) were studied. Additional inclusion criteria were
the presence of both an arterial catheter and PAC
(Edwards LifeSciences, Irvine, CA, USA) (either COTD
or CCO). Exclusion criteria were evidence of cardiac
contractility dysfunction (ejection fraction < 45% by
intraoperative echocardiography), pregnancy, having
pacemaker or automated implantable cardioverter-defi-
brillator, persistent arrhythmias, heart and/or lung trans-
plant, severe valvular (mitral, aortic, pulmonic or
tricuspid) stenosis or insufficiency after surgery, intra-
aortic balloon pump or other mechanical cardiac
support.
Patients were admitted to the ICU on assist control
ventilatory mode with 12/min respiratory rate (no
patient had a spontaneous respiration > 16/min) and 6
ml/kg tidal volume, inspiratory-to-exporatory (I/E) time
o f1 : 2a n d5c mH 2O positive end-expiratory pressure.
Fentanyl (25-50 μg) was given as needed by nursing
staff if the patient appeared to have pain or discomfort.
FloTrac™ and PAC
The FloTrac™ pulse contour device (Vigileo™, Edwards
LifeSciences, Irvine, CA, USA) was attached to the exist-
ing arterial cannula, and its sensor was attached to the
processing or display unit to read CO. The patient’s
demographic data (height, weight, age, and gender) were
entered into the device as recommended by the manu-
facturer. FloTrac CO is reported as an averaged value
over 20 seconds using a proprietary algorithm [23]. All
continuous CO measurements were collected from the
Vigileo™ monitor and input into a WinDaq data acquisi-
tion system (WINDAQ V 1.26, Dataq Instruments Inc.,
Akron, OH) as previously described [24].
Either a COTD or a CCO was measured by a standard
PAC attached to Vigilance™ monitor (Edwards Life-
Sciences, Irvine, CA). If a non-CCO PAC was present,
then CO measurements were taken upon patient arrival
to the ICU and then after each therapeutic intervention
as described below. COTD was taken as the mean of at
least three 10-ml 5°C 0.9 N NaCl bolus injections ran-
dom to the respiratory cycle. The accuracy and accept-
ability of each thermal decay curve was judged visually
on the attached ICU monitor. If CCO PAC was present,
then all CCO data based on STAT values were continu-
ously collected until end of the study using the WinDaq
data acquisition.
LiDCO plus™ and PiCCO plus™
Arterial wave form data was collected using the WinDaq
data acquisition system as previously described [24]. These
waveforms were then reinjected into both the LiDCO
plus™ and PiCCO plus™ devices offline to calculate CO. To
minimize differences due to initial calibration variance,
both the LiDCO plus™ and PiCCO plus™ devices had their
initial CO values taken from the simultaneous PAC-
derived CO values at time 0 as recommended by the man-
ufacturers, after which time neither device was recali-
brated. All continuous LiDCO and PiCCO CO
measurements were collected in a data acquisition system
installed internally in the device. The clocks on the all data
acquisition systems were matched. All the COTD measure-
ments were taken by one investigator (MH).
Protocol
We compared the mean paired CO values 30 s before
and 1-2 min after ending a volume challenge and after
heart rate and blood pressure stabilized (< 5% variation
over 30 s) following changes in vasoactive and inotropic
therapy. We made no attempt to alter the usual care of
the patients. The FloTrac data were blinded to the pri-
mary care physicians. All paired event data were down-
loaded in a common Microsoft Excel (Microsoft Corp.,
Redmond, WA, USA) spreadsheet for statistical analysis.
Statistical analysis
We performed analysis of variance for comparison of
mean baseline CO between the three devices. A post hoc
Student’s paired t-test was used to compare groups when
significance was identified. P < 0.05 was considered signifi-
cant. We performed Bland-Altman analysis for paired
devices PAC-LiDCO, PAC-PiCCO, PAC-FloTrac, LiDCO-
PiCCO, LiDCO-FloTrac and PiCCO-FloTrac. Bias was
defined as the mean difference between CO measurements
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of agreement were defined as ± 1.96 standard deviation
(SD) of the bias. The percentage error was calculated as
limits of agreement divided by the mean CO [25,26]. Bias,
limits of agreement and percentage error were calculated
for the entire data set for each set of paired devices and
then separately for COTD and CCO. We also performed
two additional Bland-Altman analyses. We selectively
compared limits of agreement and bias of CO values < 5L/
min to ascertain whether any observed bias was selectively
due to higher flow rates, which would have less clinical
relevance. Since there is no reference CO measure, we
also created a pooled CO measure as the mean of all the
devices’ CO values at one point (Z-statistic) and per-
formed a Bland-Altman analysis of each device against
this mean of all devices. For this analysis, we pooled the
PAC COtd and CCO values into one variable. Since direc-
tional changes in CO are important in assessing response
to therapy, the degree of concordance was defined as the
percentage of the total number of events when paired
devices showed the same directional change in CO
(greater than ± 0.5 L/min) divided by the total number of
events using a Pearson product-moment correlation coef-
ficient analysis. We assumed that all paired CO data that
varied by < 0.5 L/min reflected no change and then calcu-
lated the percentage of paired data points when both
devices reported no change or a change of > 0.5 L/min in
the same direction. We also calculated the correlation of
the dynamic changes in these paired values using simple
linear correlation analysis.
Results
Table 1 reports patient demographics. Simultaneous CO
measurements for all four devices in 17 patients were
taken. Two patients were excluded from analysis because
of arrhythmias and another was excluded because the
arterial pressure waveforms recorded were unusable for the
P i C C Od e v i c e .T a b l e2r e p o r t sC Ob yd e v i c ea n dt r e a t m e n t
intervention characteristics. Although mean CO values for
PAC, LiDCO, PiCCO and FloTrac were not different (5.6
± 1.5, 5.4 ± 1.6, 5.4 ± 1.5 and 6.1 ± 1.9 L/min, respectively),
mean FloTrac CO values were slightly higher than others,
approaching statistical significance between PAC, LiDCO
and PiCCO (P=0.095, 0.120 and 0.078, respectively).
The mean CO bias between each paired method was
-0.18 (PAC-LiDCO), 0.24 (PAC-PiCCO), -0.43 (PAC-
FloTrac), 0.06 (LiDCO-PiCCO), -0.63 (LiDCO-FloTrac)
and -0.67 L/min (PiCCO-FloTrac), with limits of agree-
ment (1.96 SD, 95% CI) of ± 1.56, ± 2.22, ± 3.37, ± 2.03,
±2 . 9 7a n d±3 . 4 4L / m i n ,r e s p e c t i v e l y( F i g u r e1 ) .T h e
percentage error for each set of paired devices was 29%,
41%, 59%, 39%, 53% and 61%, respectively.
Since CO accuracy may be clinically more important
at low CO values, we analyzed the agreement among
estimates of CO for mean values ≦5L / m i n .F o rC O
values ≦5 L/min, bias and limits of agreement were
-0.17 ± 1.58 (PAC-LiDCO), 0.27 ± 1.84 (PAC-PiCCO),
Table 1 Patient demographic data
a
Age (yr) 73 ± 9
Gender (M/F) 11/6
LVEF (%) 52 ± 8
Type of PAC (COTD/CCO) 10/7
Arterial catheter site (femoral/radial) 9/8
Type of operation Number
CABG 8
AVR 2
MVR 1
AVR + MVR 1
CABG + AVR 3
TAAR 1
CABG + AVR +TAAR 1
aData are presented as means ± SD. LVEF, left ventricular ejection fraction;
PAC, pulmonary artery catheter; COTD/CCO, intermittent bolus thermodilution/
continuous cardiac output; CABG, coronary artery bypass grafting; AVR/MVR/
TVR, aortic/mitral/tricuspid valve repair or replacement; TAAR, thoracic aortic
aneurysm repair, n = 17.
Table 2 Mean cardiac output measurements
a
Baseline CO (L/min), n = 17 using both COTD and CCO
PAC (COTD/CCO) 5.6 ± 1.5
LiDCO Plus 5.4 ± 1.6
PiCCO 5.4 ± 1.5
FloTrac/Vigileo 6.1 ± 1.9
Baseline CO (L/min), n = 10 using COTD
COTD PAC 6.0 ± 1.3
LiDCO Plus 5.9 ± 1.3
PiCCO 6.0 ± 1.3
FloTrac/Vigileo 6.9 ± 1.5
Baseline CO (L/min), n = 7 using CCO
CCO PAC 4.8 ± 1.4
LiDCO Plus 4.5 ± 1.8
PiCCO 4.3 ± 1.5
FloTrac/Vigileo 4.8 ± 1.7
Therapeutic interventions Number
Vasodilator (any Δ > 0.1 μg/kg/min in nitroprusside
infusion)
34
Vasoconstrictor (any Δ > 0.01 μg/kg/min in
norepinephrine or phenylephrine infusion)
8
Volume challenge (any volume > 250 cc of PRBC, FFP,
platelets or 0.9% saline given over < 30 min)
8
Inotrope (any Δ > 0.01 μg/kg/min in epinephrine or >
1 μg/kg/min in dopamine or dobutamine infusion)
10
Combination of any two or more interventions
simultaneously
66
aData are presented as means ± SD, and for characteristics of the events, total
number. PAC, pulmonary artery catheter; COTD/CCO, intermittent bolus/
continuous cardiac output; Δ, change; PRBC, packed red blood cells; FFP, fresh
frozen plasma.
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Page 3 of 100.30 ± 1.00 (PAC-FloTrac), 0.04 ± 0.91(LiDCO-PiCCO),
-0.10 ± 1.56 (LiDCO-FloTrac) and -0.27 ± 1.86 L/min
(PiCCO-FloTrac) (Figure 2).
The mean CO bias between each device and the
pooled group CO values, noting individual device var-
iance from the group mean, was -0.2 (LiDCO), 0.4 (Flo-
Trac), -0.2 (PiCCO) and 0.0 L/min (PAC), with limits of
agreement (1.96 SD, 95% CI) of ± 1.2 ± 2.4 ± 1.6 and ±
1.4, respectively (Figure 3).
PAC COtd vs. CCO as reference points
The bias and limits of agreement for each paired
method in subgroup analyses of patients with either
COTD or CCO PAC are shown in Figure 4. The bias
and limits of agreement for LiDCO with CCO (-0.31 ±
1.41 L/min), PiCCO with CCO (0.49 ± 1.30 L/min)
and FloTrac with CCO (0.05 ± 1.30 L/min) were dif-
ferent from that of the three devices with COTD PAC
(-0.10 ± 1.64, 0.09 ± 2.58 and -0.72 ± 4.09 L/min,
respectively).
The directional changes between any two paired CO
measurements from before and after each intervention
displayed 74% (PAC-LiDCO), 72% (PAC-PiCCO), 59%
(PAC-FloTrac), 70% (LiDCO-PiCCO), 71% (LiDCO-Flo-
Trac) and 63% (PiCCO-FloTrac) concordance but poor
correlation (r
2 = 0.36, P< 0.0001; r
2 = 0.11, P =0 . 0 2 5 ;
r
2 =0 . 0 8 ,P =0 . 0 7 9 ;r
2 =0 . 2 0 ,P =0 . 0 0 2 ;r
2 =0 . 2 3 ,P =
0.001; and r
2 = 0.11, P = 0.033, respectively) (Figure 5).
Discussion
DO2-targeted resuscitation protocols reduce both length
of stay and infectious complications in high-risk surgical
patients [27,28]. Several minim a l l yi n v a s i v em o n i t o r i n g
devices have been used to realize these benefits. Our
study demonstrates that the three commercially available
CO monitoring devices report similar mean CO values,
but dynamic trends among these devices over clinically
relevant CO changes are not consistent. Thus, in the pre-
sence of no contradictory findings, one must use moni-
tors specifically used in a proven effective treatment
Figure 1 Bland-Altman analysis of each set of paired devices’ cardiac output (CO). Solid line, mean difference (bias); dotted lines, limit of
agreement (bias ± 1.96 standard deviation (SD)).
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context, PAC, LiDCO plus™ and FloTrac postoptimization
protocols have been shown to improve patient-
centered outcome [27,29,30]. Surprisingly, no comparable
PAC data-specific clinical trials have been reported. We
are unable to comment on the ability of FloTrac™-o r
PiCCO plus™-guided therapy to improve outcome because
they have not been studied in this context. However, on
the basis of our analysis of 55 quadruple measures and the
three recent clinical trials [18-21,31], it is doubtful that
their performance, using the present proprietary iterations,
will be interchangeable with PAC or result in any better
outcomes than were observed using the LiDCO plus™ CO
estimates to target DO2 levels.
This clinical study is unique for two specific reasons.
First, we studied three commercially available pulse con-
tour-pulse power analysis devices that report continuous
CO measures and compared them to each other and to
two types of PAC CO estimates: COtd or CCO. Since
none of these devices is a “gold standard,” the three
pulse contour devices were compared to each other and
to the PAC as equal devices. Our comparisons show
that LiDCO plus™ and PAC have greater agreement with
each other than do either PiCCO plus™ or FloTrac™ with
PAC. Furthermore, the limits of agreement between
LiDCO plus™ and PAC are within the boundaries of the
Critchey-Critchey criteria [25], whereas those of PiCCO
plus™ or FloTrac and PAC exceed those criteria. This
close correlation also agrees with our previous data dur-
ing open heart surgery, wherein we documented that
the LiDCO plus™ estimates of stroke volume accurately
trend actual left ventricular stroke volume measures
during rapid and dynamic changes in CO when aortic
flow was accurately measured in humans using an elec-
tromagnetic flow probe placed around the ascending
aorta [32]. These levels of agreement difference persist
when all devices are compared to a mean pooled CO
value of the group as opposed to each other separately
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Figure 2 Bland-Altman analysis of each set of paired devices’ cardiac output (CO) ≤5L / m i n .S o l i dl i n e ,m e a nd i f f e r e n c e( b i a s ) ;d o t t e d
lines, limits of agreement (bias ± 1.96 SD).
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Page 5 of 10Figure 3 Bland-Altman analysis of each device against the mean of all devices across all patients, wherein pulmonary arterial catheter
(PAC) thermodilution CO (COtd) and continuous CO (CCO) are pooled to be one variable (Z-statistic). Solid line, mean difference (bias);
dotted line, limits of agreement (bias ± 1.96 SD).
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Figure 5 Pearson product-moment analysis of change in cardiac output (ΔCO; in L/min) by each set of paired devices. Dotted lines, CO
of ± 0.5 L/min.
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resuscitation interventions (volume loading, vasoactive
drug use and inotropic agent use) which reflect clinically
relevant scenarios. To date, all published validation stu-
d i e sc i t e da b o v ee x a m i n e do n l yt h ea b i l i t yo ft h e s e
devices to track cardiac output changes in response to
volume loading when vasoactive drug therapy was held
constant. Although changes in CO in response to
volume loading are very important to document, the
impact of other vasoactive therapies are equally impor-
tant, commonly seen in the clinical setting and poten-
tially confounding to the accuracy of pulse pressure-
derived estimates of CO.
In support of our findings, recent studies with Flo-
Trac™ showed limited accuracy compared to PAC
[18,19,31]. Mayer et al. [31] showed in intraoperative
cardiac surgery patients that FloTrac™ displayed an over-
all percentage error of 46% compared to paired COtd
values. Potentially, these previous studies unfairly stu-
died FloTrac™ by using profound vasomotor paralysis
and flow labile states, a clinical limitation specifically
cautioned by the manufacturer. Our FloTrac™ device
was equipped with the second-generation software mod-
i f i e dt ob em o r ea c c u r a t ei nl a b i l es t a t e s .H o w e v e r ,
Compton et al. [33] reported continued poor limits of
agreement between this second-generation FloTrac™
algorithm and PiCCO plus™ thermodilution CO mea-
sures. Thus, our FloTrac™-PAC data agree with their
findings. FloTrac™ has subsequently developed a third-
generation software algorithm that we did not use. We
do not know if this newer iteration will improve Flo-
Trac™ accuracy, since that modification allowed Flo-
Trac™ CO estimates to remain accurate during
decoupling states, such as sepsis, which were conditions
not present in our cohort. Conversely, PiCCO plus™
calibration appears to remain accurate within 6 h of
calibration even when vascular tone has been changed
[34].
We had nearly equal numbers of patients studied with
COTD and CCO PAC. This allowed us to compare these
measures with pulse contour analysis. Since both COTD
and CCO are clinically acceptable as part of standard of
care in the ICU, this distribution of patients makes our
data more robust as a reference for standard ICU care.
Regrettably, both FloTrac™ and LiDCO Plus™ CO values
h a dp o o rb i a sa n dp r e c i s i o nw i t hP A C - d e r i v e dC O
values for both COtd and CCO. These findings are also
consistent with the findings of others [18,19,35-37].
S i n c ew ed i dn o tc o m p a r eC O t dt oC C Oi nt h es a m e
patient because of the observational nature of our study,
we cannot comment on the potential bias between
COtd and CCO. However, independently of which PAC
method was used for these comparisons, neither gives
actual instantaneous measures of CO. COtd measures
require the averaging of three to five separate measures
taken over a 5-min interval. If cardiac output is systema-
tically changing during this interval (that is, either
increasing or decreasing from the start to the end of the
series of thermodilution measures), the calculated CO
value may not reflect instantaneous CO values taken at
t h es a m et i m e .S i m i l a r l y ,C C Ou s e sam o v i n ga v e r a g e
algorithm that examines thermal dilution of 3 min, mak-
ing it highly insensitive to rapid changes in CO. How-
ever, in our study, we were concerned only with
defining the data collection times as those following spe-
cific therapeutic interventions when hemodynamic mea-
sures, including heart rate, CO and mean arterial
pressure, were constant. Although such statements of
stability are relative considering the unstable nature of
the postoperative cardiac surgery patient, for the pur-
poses of CO measures they were stable over the 5 min
of data collection.
Since absolute CO measuresb e c o m ei n c r e a s i n g l y
more important at low CO values [38,39], we assessed
agreement among our monitoring devices by post hoc
analysis of all measured CO values ≤5 L/min. We found
that the degree of bias decreased slightly relative to the
complete CO data set, although the degree of variability
among the devices remained (Figure 2). Accordingly,
LiDCO Plus™,P i C C OP l u s ™ and FloTrac™ cannot be
assumed to be interchangeable with PAC devices in the
assessment of low CO values. Again, which device, if
any, reports the most accurate value and trend during
low flow states is not known on the basis of our study.
Furthermore, most of the variance between LiDCO™ and
FloTrac™ with PAC-derived CO measures came from
the COTD values, and then when these cardiac output
values were > 5 L/min. This finding is the opposite of
what Opdam et al. found [18]. Potentially, averaging CO
measurements over 20 s improved agreement between
the devices and CCO as opposed to those and COTD
PAC. This difference between CCO and COtd may
reflect the clinical decision bias by which patients with
intrinsically lower CO get CCO devices (4.8 ± 1.4 l/
min), whereas those with high CO get COTD devices
(6.0 ± 1.3 l/min).
One major potential benefit of using CCO monitoring
is to note directional changes in flow. By Pearson pro-
duct-moment analysis, we found poor correlation
between each device pair, with the best correlation
between LiDCO Plus™ and FloTrac™. PiCCO Plus™ Pear-
son product-moment analysis accuracy was intermediate
between LiDCO™ and FloTrac™.
That these devices differed in their paired perfor-
mances is not surprising. They all use different aspects
of the arterial pulse and rely on different assumptions in
their CO estimations. Most of our patient cohort was
being administered varying levels of vasoactive
Hadian et al. Critical Care 2010, 14:R212
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Page 8 of 10medications that must alter their vasomotor tone at
baseline and over time. Since LiDCO Plus™ and Flo-
Trac™ use similar aspects of the arterial pulse to calcu-
late CO, this may explain their better concordance by
Pearson product-moment analysis. Also, volume chal-
lenge in preload-responsive patients increases CO by >
10%-15% [33,40]. We used this threshold CO value as a
minimal CO change and still observed poor agreement
between devices.
Study limitations
First, we report on a small patient cohort, limiting sub-
group analysis and potentially showing differences when
a larger number of patients would show similarity. Not
all patients received all therapies, since our study was
observational. Still, this limitation reflects real-life condi-
tions. Yet, patients are treated individually, not as group
means, thus these data are relevant to clinical decision
making. Second, we did not use the PiCCO™ or LiDCO™
device-specific calibration methods. However, our com-
mon baseline external calibration method is approved
by both manufacturers as an acceptable method. Since
our goal was to ascertain the dynamic accuracy of these
devices, we reasoned that starting from a common CO
value using an external calibration method would maxi-
mize potential CO agreements between devices. If any-
thing, separate PiCCO™ and LiDCO™ calibrations would
produce more, not less, CO variance than we report.
Third, we compared not only mean CO values but also
their changes and Pearson product-moment analysis as
recommended by Squara et al. [21]. They also recom-
mended assessment of dynamic real-time trends as a
fourth method of analysis. We did not use this fourth
method of comparison, because COtd did not lend itself
to it. Finally, not all of our patients had femoral arterial
catheters, which might have affected the result of
PiCCO™ CO estimates, as large peripheral arteries are
their preferred sites. However, the femoral (central
arterial) site requirement is such that the thermal cali-
bration signal can pass the sensing thermistor not for
subsequent CO estimates. The manufacturer allows for
radial site insertion with external calibration. Further-
more, we saw no systematic differences in agreement
from femoral and radial site PiCCO CO measures.
Thus, the PiCCO data reflect the accurate values.
Conclusions
LiDCO Plus™, PiCCO™, FloTrac™ and PAC did not show
similar CO trending results, although all produced simi-
lar pooled steady-state CO values. Furthermore, if clini-
cal trials of resuscitation based on CO values show
efficacy when using one of these devices, it is not clear
whether performing the identical trial with another CO
monitoring device will also show similar benefit. Thus,
until the agreement among minimally invasive CO mea-
suring devices improves, each device needs to have its
own clinical efficacy validated.
Key messages
￿ Since the PAC-derived estimates of cardiac output
by the thermodilution technique are not the gold
standard for estimating cardiac output at the bed-
side, all available measures of cardiac output need to
be compared to each other rather than to a PAC
reference.
￿ Different commercially available arterial pressure-
derived estimates of cardiac output give differing
degrees of error relative to each other.
￿ The cardiac output error among devices is low for
cardiac output values < 5 L/min.
￿ Studies documenting clinical benefit using cathe-
ter-derived estimates of cardiac output to drive
resuscitation algorithms using one monitoring device
cannot be extrapolated to similar utility by using
another cardiac output monitoring device.
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